MGNX customers relationship map

MacroGenics (MGNX): Customer and partner relationships that fund a capital‑light R&D pivot

MacroGenics is a discovery‑stage biopharma that monetizes its antibody platform primarily through licensing, milestone receipts, royalties and targeted asset sales, while selectively providing contract manufacturing services that create episodic service revenue. Its business model deliberately converts R&D programs into non‑dilutive funding via large biopharma partnerships and asset transactions, with product sales historically concentrated in a single marketed asset until its 2024 divestiture of global rights. For an enterprise‑level snapshot and further relationship mapping, see NullExposure’s broader coverage: https://nullexposure.com/.

Why relationships matter to MacroGenics’ valuation

MacroGenics runs a hybrid commercial‑collaboration model: it sells or licenses assets to larger partners who fund late‑stage development and commercialization, while retaining upside through milestones and royalties and selectively performing manufacturing services that generate cash flow and cost reimbursement. That structure provides near‑term liquidity without equity dilution, but concentrates revenue risk on a handful of counterparty agreements and milestone events.

Key customer and partner relationships (explicit coverage)

Below I list every partner and customer referenced in the source results, with a concise, investor‑oriented description and the originating citation.

TerSera Therapeutics (TerSera Therapeutics LLC)

MacroGenics sold global rights to MARGENZA to TerSera in November 2024 for an upfront payment of $40.0 million and entered into a manufacturing services arrangement tied to MARGENZA production that pays MacroGenics according to a manufacturing schedule and reimburses materials and costs. Source: FY2024 Form 10‑K (MARGENZA sale and manufacturing services).

Ajinomoto Bio‑Pharma Services

Ajinomoto is listed as a primary contract fill‑finish provider that MacroGenics relies on to fulfill fill‑finish needs for current and future product candidates. Source: FY2024 Form 10‑K (fill‑finish providers).

Emergent BioSolutions (EBS)

MacroGenics entered into agreements with Emergent in August and December 2023 to provide manufacturing services to produce certain Emergent bulk drug substances, receiving payments per schedule and reimbursement for materials and costs. Source: FY2024 Form 10‑K (manufacturing agreements with Emergent).

Gilead Sciences (GILD)

MacroGenics and Gilead signed an exclusive option and collaboration agreement (October 2022) to develop and commercialize MGD024 and to create up to two bispecific research programs; the partnership has generated significant upfront/partnering proceeds and leaves MacroGenics eligible for up to roughly $1.6–$1.7 billion in future milestones plus royalties for the covered programs. Sources: FY2024 Form 10‑K (Gilead Agreement) and company press reporting (GlobeNewswire Q3 2025; FierceBiotech FY2022; Globenewswire/Q1 2026 releases).

Incyte Corporation (INCY)

MacroGenics licensed retifanlimab (MGA012) to Incyte under a global collaboration (2017) and continues to be eligible for milestone payments and to provide manufacturing services; milestones under the Incyte agreement drove a large portion of MacroGenics’ revenue recognition in 2024 (roughly $100.0 million recognized in 2024). MacroGenics retains limited development rights for combination strategies. Sources: FY2024 Form 10‑K (Incyte license) and Globenewswire/Q4 reporting (milestone recognition).

DRI Healthcare Trust / DHTRF

MacroGenics sold its royalty interest on future global net sales of TZIELD to a wholly‑owned subsidiary of DRI Healthcare Trust for up to $200 million, creating a monetization of royalty cash flows. Source: CityBiz / MacroGenics press coverage (royalty sale announcement; FY2023 reporting context).

Sanofi S.A. (and Provention)

Sanofi (through subsequent corporate acquisitions) is the commercial partner advancing TZIELD worldwide; MacroGenics sold related rights earlier and remains eligible for milestone payments tied to TZIELD (up to $330 million reported). Provention (the intermediate asset purchaser) also appears in milestone recognition discussions—MacroGenics recognized $50.0 million from the Provention (Sanofi) Asset Purchase Agreement in 2025. Sources: Globenewswire (Q3 2025 reporting) and Bitget/GlobeNewswire FY2026 releases.

Zai Lab (ZLAB)

Under a November 2018 license and collaboration agreement, Zai Lab received rights to develop margetuximab (MARGENZA) in mainland China, Hong Kong, Macau and Taiwan, representing MacroGenics’ strategy of regional licensing to accelerate market access. Source: FY2024 Form 10‑K (license and collaboration with Zai Lab).

Merck, Servier and Kyowa Kirin

MacroGenics lists strategic partnerships with Merck, Servier and Kyowa Kirin that have supported late‑stage development, regulatory filings and potential commercialization outside the U.S., underscoring the company’s international licensing strategy. Source: MarketBeat / analyst note coverage (FY2026 context).

What the contract and relationship constraints reveal about operations

Spot product contracts and distributor/reseller channeling dominate product sales. The company reports customer contracts as single performance obligations satisfied on delivery — a spot sale model — and product sales are routed primarily through specialty distributors that resell to healthcare providers. This indicates low recurring contract duration for product revenue but standard commercial trade flows through distributor partners. Source: company disclosures in FY2024 Form 10‑K (contract revenue recognition language and distributor/reseller mention).
Service provider engagements are structured as fee‑for‑service with reimbursement. MacroGenics performs manufacturing services for customers (explicitly for TerSera, Emergent and Incyte in its filings), receiving scheduled payments and reimbursement for materials and costs, which converts some program activity into short‑term cash flow without transferring technical IP. Source: FY2024 Form 10‑K (service agreements naming TerSera, Emergent and Incyte).
Core product concentration is material. Product sales historically reflected MARGENZA revenue until MacroGenics sold global rights in 2024, indicating a prior concentration of product revenue in a single marketed asset; post‑divestiture, MacroGenics is more dependent on milestone and partnership proceeds for near‑term revenue. Source: FY2024 Form 10‑K (product sales note and MARGENZA sale).
Revenue mix is skewed toward milestone and licensing cash events. Recent financial reporting shows large, annual swings tied to milestone recognition (e.g., $100M from Incyte in 2024 vs. $50M from the Provention agreement in 2025), creating lumpy top‑line dynamics tied to partner decisions and regulatory timing. Source: Globenewswire (Q3 2025 and FY2025 reporting).

Investment implications and near‑term catalysts

Upside drivers: milestone realizations from Gilead, Incyte and Sanofi/TZIELD royalties and the Gilead opt‑ins and program advancement represent the primary near‑term value drivers and non‑dilutive capital sources. Globenewswire and company filings list substantial potential milestone pools tied to these partnerships.
Key risks: revenue concentration in partner milestones, reliance on a small set of large partners and the spot/delivery nature of product contracts introduce revenue volatility; manufacturing service income is episodic and tied to partner schedules.

For investors monitoring MacroGenics, the next material events are scheduled program opt‑ins, clinical readouts under the Gilead collaboration (MGD024 and others), and milestone recognitions under Incyte and TZIELD partner agreements. For continual updates on counterparty exposure and relationship analytics, consult NullExposure’s company pages: https://nullexposure.com/.

Bold takeaway: MacroGenics has successfully re‑engineered its funding model from product sales toward strategic partnerships and targeted asset monetizations, converting R&D risk into milestone‑based value that is large but lumpy and partner‑dependent.

MGNX customer relationships